The PALLAS study demonstrated that the addition of palbociclib to adjuvant endocrine therapy for 2 years did not improve invasive disease-free survival (iDFS) in HR+/HER2-early-stage breast cancer (eBC) (32). Here, ERBB2 is linked to breast cancer.